Harry R Buller

Summary

Affiliation: Academic Medical Center
Country: The Netherlands

Publications

  1. ncbi request reprint Factor Xa is a superior target to factor IIa for antithrombotic therapies
    Harry R Buller
    Department of Vascular Medicine, Academic Medical Center University of Amsterdam, The Netherlands
    Semin Thromb Hemost 29:37. 2003
  2. ncbi request reprint General discussion
    Harry Buller
    Department of Vascular Medicine, Academic Medical Center, NL 1100 DD Amsterdam, The Netherlands
    Pathophysiol Haemost Thromb 34:31-4. 2005
  3. ncbi request reprint Treatment of venous thromboembolism
    H R Buller
    Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands
    J Thromb Haemost 3:1554-60. 2005
  4. ncbi request reprint Introduction
    Harry Buller
    Department of Vascular Medicine, Academic Medical Center, NL 1100 DD Amsterdam, The Netherlands
    Pathophysiol Haemost Thromb 34:1. 2005
  5. ncbi request reprint Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism
    H R Buller
    Academic Medical Center, Department of Vascular Medicine, F4 211, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands
    N Engl J Med 349:1695-702. 2003
  6. ncbi request reprint Extended prophylaxis of venous thromboembolism with idraparinux
    Harry R Buller
    Academic Medical Center, Department of Vascular Medicine, F4 211, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands
    N Engl J Med 357:1105-12. 2007
  7. ncbi request reprint Endotoxaemia induces resistance to activated protein C in healthy humans
    Anne Cornelie J M de Pont
    Department of Intensive Care, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands
    Br J Haematol 134:213-9. 2006
  8. ncbi request reprint Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial
    Harry R Buller
    Department of Vascular Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
    Ann Intern Med 140:867-73. 2004
  9. ncbi request reprint Predilution versus postdilution during continuous venovenous hemofiltration: a comparison of circuit thrombogenesis
    Anne Cornelie J M de Pont
    Departments of Intensive Care, Academic Medical Center, University of Amsterdam, The Netherlands
    ASAIO J 52:416-22. 2006
  10. ncbi request reprint Treatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trials
    Frederiek F van Doormaal
    Academic Medical Center, Amsterdam, The Netherlands
    Thromb Haemost 101:762-9. 2009

Detail Information

Publications76

  1. ncbi request reprint Factor Xa is a superior target to factor IIa for antithrombotic therapies
    Harry R Buller
    Department of Vascular Medicine, Academic Medical Center University of Amsterdam, The Netherlands
    Semin Thromb Hemost 29:37. 2003
  2. ncbi request reprint General discussion
    Harry Buller
    Department of Vascular Medicine, Academic Medical Center, NL 1100 DD Amsterdam, The Netherlands
    Pathophysiol Haemost Thromb 34:31-4. 2005
  3. ncbi request reprint Treatment of venous thromboembolism
    H R Buller
    Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands
    J Thromb Haemost 3:1554-60. 2005
    ..This section describes the current recommendations about how to treat patients with VTE initially and long term. Finally, in the third section the challenges for the treatment of patients beyond 2005 are discussed...
  4. ncbi request reprint Introduction
    Harry Buller
    Department of Vascular Medicine, Academic Medical Center, NL 1100 DD Amsterdam, The Netherlands
    Pathophysiol Haemost Thromb 34:1. 2005
  5. ncbi request reprint Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism
    H R Buller
    Academic Medical Center, Department of Vascular Medicine, F4 211, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands
    N Engl J Med 349:1695-702. 2003
    ..The standard initial treatment of hemodynamically stable patients with pulmonary embolism is intravenous unfractionated heparin, requiring laboratory monitoring and hospitalization...
  6. ncbi request reprint Extended prophylaxis of venous thromboembolism with idraparinux
    Harry R Buller
    Academic Medical Center, Department of Vascular Medicine, F4 211, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands
    N Engl J Med 357:1105-12. 2007
    ..We evaluated the efficacy and safety of a 6-month extension of prophylaxis against recurrent venous thromboembolism with idraparinux in patients who had initially received 6 months of prophylaxis with an anticoagulant...
  7. ncbi request reprint Endotoxaemia induces resistance to activated protein C in healthy humans
    Anne Cornelie J M de Pont
    Department of Intensive Care, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands
    Br J Haematol 134:213-9. 2006
    ..In vitro tests confirmed that an increase in factor VIII induced APC resistance, as measured by both tests. This finding suggests that APC resistance might play a role in the procoagulant state occurring during human endotoxemia...
  8. ncbi request reprint Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial
    Harry R Buller
    Department of Vascular Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
    Ann Intern Med 140:867-73. 2004
    ..In a dose-ranging study of patients with symptomatic deep venous thrombosis, fondaparinux had efficacy and a safety profile similar to those of low-molecular-weight heparin (dalteparin)...
  9. ncbi request reprint Predilution versus postdilution during continuous venovenous hemofiltration: a comparison of circuit thrombogenesis
    Anne Cornelie J M de Pont
    Departments of Intensive Care, Academic Medical Center, University of Amsterdam, The Netherlands
    ASAIO J 52:416-22. 2006
    ..In summary, predilution and postdilution did not differ with respect to extracorporeal circuit thrombogenesis. During postdilution, baseline platelet count and maximal prefilter pressure were inversely related with circuit survival time...
  10. ncbi request reprint Treatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trials
    Frederiek F van Doormaal
    Academic Medical Center, Amsterdam, The Netherlands
    Thromb Haemost 101:762-9. 2009
    ..No significant differences in recurrent VTE were observed when comparing fondaparinux with unfractionated or LMWH. Because of study limitations these results should be considered hypothesis-generating...
  11. doi request reprint Prolactin and venous thrombosis: indications for a novel risk factor?
    Bregje van Zaane
    Department of Internal Medicine, Slotervaart Hospital, Louwesweg 6, 1066 EC, Amsterdam, The Netherlands
    Arterioscler Thromb Vasc Biol 31:672-7. 2011
    ..Several acquired risk factors for venous thrombosis (VT) are associated with high prolactin levels. Our goal was to investigate VT risk for different levels of prolactin...
  12. doi request reprint New anticoagulants: moving on from scientific results to clinical implementation
    Elise S Eerenberg
    Department of Vascular Medicine, Academic Medical Centre, Amsterdam, The Netherlands
    Ann Med 43:606-16. 2011
    ..Lack of information on the proper monitoring method or antidote in case of bleeding may also hinder the translation from science to clinical practice...
  13. doi request reprint Idraparinux versus standard therapy in the treatment of deep venous thrombosis in cancer patients: a subgroup analysis of the Van Gogh DVT trial
    Frederiek F van Doormaal
    Department of Vascular Medicine, Academic Medical Center, Meibergdreef 9, Amsterdam, The Netherlands
    Thromb Haemost 104:86-91. 2010
    ..Fewer recurrent VTEs were observed in the idraparinux group; however, this was not statistically significant and also because of study limitations this should be interpreted with caution...
  14. doi request reprint Acute pulmonary embolism. Part 2: treatment
    Josien van Es
    Department of Vascular Medicine, Academic Medical Center, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands
    Nat Rev Cardiol 7:613-22. 2010
    ..Some patients with PE can be safely treated at home, but few outcome studies in this setting have been published...
  15. ncbi request reprint Recombinant factor VIIa reverses the anticoagulant effect of the long-acting pentasaccharide idraparinux in healthy volunteers
    Nick R Bijsterveld
    Department of Cardiology, Room F3 241, Academic Medical Centre, University of Amsterdam, Meibergdreef 9, 1105 AZ, PO Box 22660, 1100 DD Amsterdam, The Netherlands
    Br J Haematol 124:653-8. 2004
    ..We conclude that rFVIIa has significant effects on the idraparinux-inhibited thrombin generation and clotting parameters. These results suggest that rFVIIa may be useful in serious bleeding complications in idraparinux treated patients...
  16. ncbi request reprint Direct thrombin inhibitors
    Marcello Di Nisio
    Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands
    N Engl J Med 353:1028-40. 2005
  17. ncbi request reprint Rebound thrombin generation after heparin therapy in unstable angina. A randomized comparison between unfractionated and low-molecular-weight heparin
    Nick R Bijsterveld
    Department of Cardiology, Academic Medical Center, Amsterdam, Netherlands
    J Am Coll Cardiol 39:811-7. 2002
    ..This study compared rebound coagulation in patients with acute coronary syndrome patients after discontinuation of unfractionated heparin (UFH) or low-molecular-weight heparin (LMWH)...
  18. ncbi request reprint Recombinant nematode anticoagulant protein c2, a novel inhibitor of tissue factor-factor VIIa activity, abrogates endotoxin-induced coagulation in chimpanzees
    Arno H M Moons
    Department of Cardiology, Academic Medical Center, Amsterdam, The Netherlands
    Thromb Haemost 88:627-31. 2002
    ..These results suggest that rNAPc2 may be a promising therapeutic option to inhibit coagulation activation in patients with sepsis...
  19. doi request reprint Thrombin-activatable fibrinolysis inhibitor in hypothyroidism and hyperthyroxinaemia
    Chantal J N Verkleij
    Department of Experimental Vascular Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
    Thromb Haemost 109:214-20. 2013
    ..The disturbed haemostatic balance in patients with hyperthyroidism might make them prone to thrombosis, while the risk for bleeding may increase in patients with hypothyroidism...
  20. ncbi request reprint A prospective cohort study on the absolute incidence of venous thromboembolism and arterial cardiovascular disease in asymptomatic carriers of the prothrombin 20210A mutation
    Michiel Coppens
    Department of Vascular Medicine F4 276, Academic Medical Center, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands
    Blood 108:2604-7. 2006
    ....
  21. ncbi request reprint Prevention and treatment of experimental thrombosis in rabbits with rivaroxaban (BAY 597939)--an oral, direct factor Xa inhibitor
    Bart J Biemond
    Department of Haematology, Academic Medical Center, University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands
    Thromb Haemost 97:471-7. 2007
    ..In conclusion, the orally available selective, direct FXa inhibitor rivaroxaban is effective in the prevention and treatment of venous thrombosis in two well-established models of experimental thrombosis...
  22. doi request reprint Statin treatment and the risk of recurrent pulmonary embolism
    Sara Biere-Rafi
    Department of Vascular Medicine, F4 140, Academic Medical Centre, Meibergdreef 9, Amsterdam 1105 AZ, The Netherlands
    Eur Heart J 34:1800-6. 2013
    ..We examined the effect of statin therapy on the risk of recurrent pulmonary embolism (PE)...
  23. ncbi request reprint Preoperative or postoperative start of prophylaxis for venous thromboembolism with low-molecular-weight heparin in elective hip surgery?
    Niklaus Strebel
    Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands
    Arch Intern Med 162:1451-6. 2002
    ..Unfortunately, the optimal regimen is uncertain because direct comparisons among these regimens with sufficiently large sample sizes are not available...
  24. ncbi request reprint Efficacy and safety of recombinant factor VIIa for treatment of severe bleeding: a systematic review
    Marcel Levi
    Department of Vascular Medicine Internal Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
    Crit Care Med 33:883-90. 2005
    ..Recombinant factor VIIa is, however, increasingly used for several other indications, including patients with a preexistent normal coagulation system but who experience serious bleeding, for example, after major surgery or trauma...
  25. ncbi request reprint Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy
    Harry R Buller
    Department of Vascular Medicine, Academic Medical Center, University of Amsterdam, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands
    Chest 126:401S-428S. 2004
    ..For most patients with pulmonary embolism (PE), we recommend clinicians not use systemic thrombolytic therapy (Grade 1A). For the duration and intensity of treatment for PE, the recommendations are similar to those for DVT...
  26. ncbi request reprint Travel and the risk of symptomatic venous thromboembolism
    Marije Ten Wolde
    Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands
    Thromb Haemost 89:499-505. 2003
    ..This study shows that the average traveller does not have an increased risk for symptomatic venous thromboembolism. Only very long travelling (more than 10 h) may be associated with venous thromboembolic disease...
  27. pmc Potential of an age adjusted D-dimer cut-off value to improve the exclusion of pulmonary embolism in older patients: a retrospective analysis of three large cohorts
    Renee A Douma
    Department of Vascular Medicine, Academic Medical Centre, Meibergdreef 9, 1105 AZ, Amsterdam, Netherlands
    BMJ 340:c1475. 2010
    ..In older patients, the the D-dimer test for pulmonary embolism has reduced specificity and is therefore less useful. In this study a new, age dependent cut-off value for the test was devised and its usefulness with older patients assessed...
  28. doi request reprint Application of a decision rule and a D-dimer assay in the diagnosis of pulmonary embolism
    Nadine S Gibson
    Department of Vascular Medicine, Academical Medical Center, Amsterdam, The Netherlands
    Thromb Haemost 103:849-54. 2010
    ..Furthermore, the knowledge of an abnormal D-dimer test result before seeing the patient leads to a higher CDR score. Physicians should therefore first examine patients before taking note of the D-dimer test result...
  29. ncbi request reprint Idraparinux versus standard therapy for venous thromboembolic disease
    Harry R Buller
    Academic Medical Center, Department of Vascular Medicine, F4 211, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands
    N Engl J Med 357:1094-104. 2007
    ..We investigated the potential use of idraparinux, a long-acting inhibitor of activated factor X, as a substitute for standard therapy...
  30. doi request reprint Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects
    Elise S Eerenberg
    Department of Vascular Medicine, Academic Medical Center, Meibergdreef 9, 1105 AZ Amsterdam, Netherlands
    Circulation 124:1573-9. 2011
    ..This study evaluated the potential of prothrombin complex concentrate (PCC) to reverse the anticoagulant effect of these drugs...
  31. ncbi request reprint The impact on coagulation of an intravenous loading dose in addition to a subcutaneous regimen of low-molecular-weight heparin in the initial treatment of acute coronary syndromes
    Nick R Bijsterveld
    Department of Cardiology, Academic Medical Center, Amsterdam, The Netherlands
    J Am Coll Cardiol 42:424-7. 2003
    ..We sought to quantify the impact of adding an intravenous loading dose to a subcutaneous regimen of enoxaparin in patients with an acute coronary syndrome (ACS)...
  32. ncbi request reprint Simplification of the diagnostic management of suspected deep vein thrombosis
    Roderik A Kraaijenhagen
    Department of Vascular Medicine, Academic Medical Center, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands
    Arch Intern Med 162:907-11. 2002
    ..We hypothesized that a normal finding of a D-dimer assay safely obviates the need for repeated ultrasonography. In addition, we evaluated the potential value of a pretest probability assessment for this purpose...
  33. ncbi request reprint Absolute annual incidences of first events of venous thromboembolism and arterial vascular events in individuals with elevated FVIII:c. A prospective family cohort study
    Ivan Bank
    Department of Vascular Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
    Thromb Haemost 98:1040-4. 2007
    ..Elevated FVIII:c may be a common risk factor for both clinical entities...
  34. doi request reprint Clinical decision rule and D-dimer have lower clinical utility to exclude pulmonary embolism in cancer patients. Explanations and potential ameliorations
    Renee A Douma
    Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands
    Thromb Haemost 104:831-6. 2010
    ..A CDR combined with an age-dependent D-dimer cut-off shows a modest improvement of the strategy in cancer patients...
  35. doi request reprint Further validation and simplification of the Wells clinical decision rule in pulmonary embolism
    Nadine S Gibson
    Department of Vascular Medicine, Academical Medical Center, Meibergdreef 9, 1105 AZ Amsterdam
    Thromb Haemost 99:229-34. 2008
    ..This study further validates the diagnostic utility of the Wells rule and indicates that the scoring system can be simplified to one point for each variable...
  36. doi request reprint Enoxaparin followed by once-weekly idrabiotaparinux versus enoxaparin plus warfarin for patients with acute symptomatic pulmonary embolism: a randomised, double-blind, double-dummy, non-inferiority trial
    Harry R Buller
    Department of Vascular Medicine, Academic Medical Centre, Amsterdam, Netherlands
    Lancet 379:123-9. 2012
    ..We aimed to assess non-inferiority of idrabiotaparinux, a reversible longlasting indirect inhibitor of activated factor X, to warfarin in patients with acute symptomatic pulmonary embolism...
  37. pmc Recombinant human activated protein C resets thrombin generation in patients with severe sepsis - a case control study
    Anne Cornelie J M de Pont
    Department of Intensive Care, Academic Medical Center, University of Amsterdam, The Netherlands
    Crit Care 9:R490-7. 2005
    ..The aim of the present study was to evaluate the dynamics of the anticoagulant, anti-inflammatory and pro-fibrinolytic action of rhAPC in patients with severe sepsis, by comparing rhAPC-treated patients with case controls...
  38. ncbi request reprint Assessment of coagulation and fibrinolysis in families with unexplained thrombophilia
    Iris M Wichers
    Dept of Vascular Medicine, F4 276, Academic Medical Center, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands
    Thromb Haemost 101:465-70. 2009
    ..We found that an increased ETP may serve as an intermediate phenotype for VTE and may be used to discover novel inherited risk factors by genetic linkage analysis...
  39. doi request reprint Cardiovascular risk assessment in haemophilia patients
    Sara Biere-Rafi
    Department of Vascular Medicine, F4 140 Academic Medical Center, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands
    Thromb Haemost 105:274-8. 2011
    ..This strengthens the hypothesis that hypocoagulability may reduce cardiovascular mortality in haemophilia patients...
  40. ncbi request reprint Levels of prolactin in relation to coagulation factors and risk of venous thrombosis. Results of a large population-based case-control study (MEGA-study)
    Danka J F Stuijver
    Department of Internal Medicine, Slotervaart Hospital, Amsterdam, The Netherlands
    Thromb Haemost 108:499-507. 2012
    ..This may be explained by a causal relation or by prolactin being a marker of stress due to the thrombotic event...
  41. pmc Increasing levels of free thyroxine as a risk factor for a first venous thrombosis: a case-control study
    Bregje van Zaane
    Department of Internal Medicine, Slotervaart Hospital, Amsterdam, The Netherlands
    Blood 115:4344-9. 2010
    ..0 (95% CI, 1.1-154.1) for FT(4) levels above reference range. Our data suggest increasing levels of FT(4) to be a risk factor for VT and may have implications for both the prevention and management of this disease...
  42. ncbi request reprint Hypercoagulable state in Cushing's syndrome: a systematic review
    Bregje van Zaane
    Department of Internal Medicine, Slotervaart Hospital, Louwesweg 6, Amsterdam, The Netherlands
    J Clin Endocrinol Metab 94:2743-50. 2009
    ..It has been debated whether an increased risk of venous thromboembolism (VTE) exists in patients with Cushing's syndrome...
  43. doi request reprint The importance of clinical probability assessment in interpreting a normal d-dimer in patients with suspected pulmonary embolism
    Nadine S Gibson
    Department of Vascular Medicine, Academical Medical Center, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands
    Chest 134:789-93. 2008
    ..The objective of this study was to investigate how often the d-dimer test fails when clinical probability is not taken into account...
  44. doi request reprint Non-selective vs. selective beta-blocker treatment and the risk of thrombo-embolic events in patients with heart failure
    Olav R de Peuter
    Department of Vascular Medicine F4 139, Academic Medical Centre, Amsterdam, The Netherlands
    Eur J Heart Fail 13:220-6. 2011
    ..We studied the influence of non-selective beta-blockers compared with selective beta-blockers on the occurrence of arterial and venous thrombo-embolic events in patients with HF...
  45. ncbi request reprint Acquired and inherited thrombophilic factors and the risk for residual venous thrombosis
    Ivan Bank
    Department of Vascular Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
    Pathophysiol Haemost Thromb 33:192-6. 2003
    ..7, 95% CI 1.2-2.2). Although these results should be confirmed in a larger study, they might help us form hypotheses concerning why patients with thrombophilia are more prone to recurrent venous thromboembolic disease...
  46. ncbi request reprint The additional value of the CRP test in patients in whom the primary care physician excluded pulmonary embolism
    Wim A M Lucassen
    Academic Medical Centre, Department of General Practice, Amsterdam, The Netherlands
    Eur J Gen Pract 19:143-9. 2013
    ..A negative D-dimer test makes clinically relevant disease less likely. The C-reactive protein (CRP) test could be of additional value to make this differentiation...
  47. pmc Improving stroke prevention in patients with atrial fibrillation
    Derk L Arts
    Department of General Practice, Academic Medical Center, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands
    Trials 14:193. 2013
    ..We investigate the use of a clinical decision support system to improve guideline adherence among general practitioners (GPs) treating patients with AF and study reasons for guideline non-adherence...
  48. doi request reprint Use of oral glucocorticoids and the risk of pulmonary embolism: a population-based case-control study
    Danka J F Stuijver
    Department of Internal Medicine, Slotervaart Hospital, Louwesweg 6, 1066 EC, Amsterdam, The Netherlands
    Chest 143:1337-42. 2013
    ..Whether exogenous use of glucocorticoids is associated with an increased risk of VTE is unclear. We aimed to quantify the risk of symptomatic pulmonary embolism (PE) in patients using corticosteroids...
  49. doi request reprint Coagulation activation and microparticle-associated coagulant activity in cancer patients. An exploratory prospective study
    Frederiek van Doormaal
    Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands
    Thromb Haemost 108:160-5. 2012
    ..However, in the patients who developed VTE within six months when compared to those who did not, an increased MP procoagulant activity was present already at baseline, suggesting this activity can be used to predict VTE...
  50. doi request reprint Comparison of 4- and 64-slice CT scanning in the diagnosis of pulmonary embolism
    Renee A Douma
    Department of Vascular Medicine, Academic Medical Center, Meibergdreef 9, Suite F4 143, 1105 AZ Amsterdam, The Netherlands
    Thromb Haemost 103:242-6. 2010
    ..In a multi-reader setting, the number of inconclusive examinations was higher than quoted for clinical management studies, indicating that the diagnosis of PE with MDCT could be less straightforward than assumed...
  51. doi request reprint A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT Dose-Ranging Study
    Harry R Buller
    Department of Vascular Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
    Blood 112:2242-7. 2008
    ..8% of those receiving standard therapy. These results with simple fixed-dose oral regimens justify phase 3 evaluations (www.ClinicalTrials.gov no.NCT00395772)...
  52. ncbi request reprint The effect of low molecular weight heparin on survival in patients with advanced malignancy
    Clara P W Klerk
    Department of Vascular Medicine, Academic Medical Center F4 139, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands
    J Clin Oncol 23:2130-5. 2005
    ..In a double-blind study, we evaluated the effect of low molecular weight heparin on survival in patients with advanced malignancy without venous thromboembolism...
  53. doi request reprint Randomized trial of the effect of the low molecular weight heparin nadroparin on survival in patients with cancer
    Frederiek F van Doormaal
    Academic Medical Center, and Slotervaart Hospital, Amsterdam, The Netherlands
    J Clin Oncol 29:2071-6. 2011
    ..This study was designed to confirm these findings in a more homogeneous group of patients with cancer...
  54. pmc Excluding pulmonary embolism in primary care using the Wells-rule in combination with a point-of care D-dimer test: a scenario analysis
    Wim A M Lucassen
    Department of General Practice, Academic Medical Centre, Amsterdam, The Netherlands
    BMC Fam Pract 11:64. 2010
    ..We considered ruling out PE safe if the failure rate was <2% with a maximum upper confidence limit of 2.7%...
  55. ncbi request reprint Effects on coagulation and fibrinolysis induced by influenza in mice with a reduced capacity to generate activated protein C and a deficiency in plasminogen activator inhibitor type 1
    Tymen T Keller
    Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands
    Circ Res 99:1261-9. 2006
    ..These findings suggest that influenza leads to a prothrombotic state by coagulation activation. Heparin treatment reduces the influenza induced prothrombotic state...
  56. ncbi request reprint Validity and clinical utility of the simplified Wells rule for assessing clinical probability for the exclusion of pulmonary embolism
    Renee A Douma
    Department of Vascular Medicine, Academic Medical Center, Meibergdreef 9, P O Box 22600, 1100 DD Amsterdam, The Netherlands
    Thromb Haemost 101:197-200. 2009
    ..In this external retrospective validation study, the simplified Wells rule appeared to be safe and clinically useful, although prospective validation remains necessary. Simplification of the Wells rule may enhance the applicability...
  57. doi request reprint Aspirin plus heparin or aspirin alone in women with recurrent miscarriage
    Stef P Kaandorp
    Department of Obstetrics and Gynecology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
    N Engl J Med 362:1586-96. 2010
    ....
  58. ncbi request reprint Incidental venous thromboembolism in cancer patients: prevalence and consequence
    Renee A Douma
    Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands
    Thromb Res 125:e306-9. 2010
    ..Careful re-evaluation of CT-scans for cancer staging frequently reveals unsuspected venous thromboembolism (VTE) on CT-scans. However, it is unknown how often these findings lead to anticoagulant treatment in daily clinical practice...
  59. ncbi request reprint Unselected women with elevated levels of factor VIII:C or homocysteine are not at increased risk for obstetric complications
    Saskia Middeldorp
    Academic Medical Center, Department of Vascular Medicine, F4 276, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands
    Thromb Haemost 92:787-90. 2004
    ..Unselected women with elevated plasma levels of FVIII:C or hyperhomocysteinemia are not at increased risk for obstetric complications as compared to their relatives with normal levels...
  60. doi request reprint Time-trends in treatment and cardiovascular events in patients with heart failure: a pharmacosurveillance study
    Olav R de Peuter
    Department of Vascular Medicine, Academic Medical Centre, Amsterdam, The Netherlands
    Eur J Heart Fail 13:489-95. 2011
    ..We assessed, in patients with a first hospitalization for heart failure (HF), the temporal relationship of the incidence of cardiovascular events, all-cause mortality, and cardiovascular drug treatment...
  61. doi request reprint Systolic heart failure: a prothrombotic state
    Olav R de Peuter
    Department of Vascular Medicine, Academic Medical Centre, University of Amsterdam, 1100 DD Amsterdam, The Netherlands
    Semin Thromb Hemost 35:497-504. 2009
    ..This article focuses on this prothrombotic state and discusses the risk of thromboembolic events, pathophysiological mechanisms, and the potential role of anticoagulant treatment...
  62. ncbi request reprint Treatment of superficial vein thrombosis to prevent deep vein thrombosis and pulmonary embolism: a systematic review
    Iris M Wichers
    Dept of Vascular Medicine, F4 276, Academic Medical Center, University of Amsterdam, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands
    Haematologica 90:672-7. 2005
    ....
  63. ncbi request reprint Treatment of symptomatic venous thromboembolism: improving outcomes
    Harry R Buller
    Department of Vascular Medicine, Academic Medical Center at the University of Amsterdam, Amsterdam, The Netherlands
    Semin Thromb Hemost 28:41-8. 2002
    ..Studies in patients undergoing major orthopedic surgery and in those with proximal DVT indicate that the efficacy and safety of fondaparinux may represent an improvement over those of LMWH...
  64. doi request reprint The role of activated protein C in cancer progression
    Geerte L Van Sluis
    Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands
    Thromb Res 125:S138-42. 2010
    ..It discusses the APC pathway as a potential novel target to influence cancer progression, but it also points to several limitations of APC administration in the setting of cancer cell metastasis...
  65. pmc Idiopathic superficial thrombophlebitis and the incidence of cancer in primary care patients
    Frederiek F van Doormaal
    Department of Vascular Medicine, Academic Medical Center Amsterdam, The Netherlands
    Ann Fam Med 8:47-50. 2010
    ..We wanted to determine the incidence of cancer after an episode of spontaneous superficial thrombophlebitis in a large general practice population...
  66. ncbi request reprint Prothrombin 20210A mutation: a mild risk factor for venous thromboembolism but not for arterial thrombotic disease and pregnancy-related complications in a family study
    Ivan Bank
    Department of Vascular Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
    Arch Intern Med 164:1932-7. 2004
    ..The aim of this study was to estimate the incidences of first venous and arterial thrombotic events and pregnancy-related complications in relatives of patients with the mutation...
  67. doi request reprint Performance of 4 clinical decision rules in the diagnostic management of acute pulmonary embolism: a prospective cohort study
    Renee A Douma
    Academic Medical Center, Amsterdam, The Netherlands
    Ann Intern Med 154:709-18. 2011
    ..Several clinical decision rules (CDRs) are available to exclude acute pulmonary embolism (PE), but they have not been directly compared...
  68. ncbi request reprint Antithrombotic therapy and cancer
    Marcello Di Nisio
    Department of Vascular Medicine and of Oncology, Academic Medical Center, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands
    Curr Opin Hematol 11:187-91. 2004
    ..To assess the current evidence from recent clinical trials investigating antithrombotic agents for the prophylaxis and treatment of venous thromboembolism in cancer patients and for the effects of these agents on cancer progression...
  69. doi request reprint Bleeding in patients receiving vitamin K antagonists who would have been excluded from trials on which the indication for anticoagulation was based
    Marcel Levi
    Department of Internal Medicine Vascular Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
    Blood 111:4471-6. 2008
    ..VKAs are often prescribed to patients who would not have qualified for clinical trials, and in these patients a careful consideration should be made regarding the expected efficacy and the risk of bleeding...
  70. doi request reprint Stress-induced hyperglycaemia and venous thromboembolism following total hip or total knee arthroplasty: analysis from the RECORD trials
    Danny M Cohn
    Department of Internal Medicine, Academic Medical Center, Amsterdam, The Netherlands
    Thromb Haemost 107:225-31. 2012
    ..8 (95%CI 1.2 to 2.8). This was not observed in patients undergoing total knee replacement, probably due to differences in the applied surgical procedures...
  71. ncbi request reprint The incidence of recurrent venous thromboembolism after treatment with vitamin K antagonists in relation to time since first event: a meta-analysis
    Carlo J J van Dongen
    Department of Clinical Epidemiology, Academic Medical Center, Amsterdam, The Netherlands
    Arch Intern Med 163:1285-93. 2003
    ..The aim of the present meta-analysis is to describe the risk of recurrent venous thromboembolism after treatment with vitamin K antagonist in relation to the time since the index event...
  72. ncbi request reprint Heparin and survival in cancer patients
    Frederiek F van Doormaal
    Department of Vascular Medicine, Academic Medical Center Amsterdam, Amsterdam, Netherlands
    Hematol Oncol Clin North Am 24:777-84, ix-x. 2010
    ..Furthermore, the potential inhibitory effect of anticoagulant drugs on cancer progression has been explored. This article discusses these two aspects of the association...
  73. pmc Endogenous activated protein C limits cancer cell extravasation through sphingosine-1-phosphate receptor 1-mediated vascular endothelial barrier enhancement
    Geerte L Van Sluis
    Department of Vascular Medicine, Center for Experimental and Molecular Medicine, Academic Medical Center, Amsterdam, The Netherlands
    Blood 114:1968-73. 2009
    ..In conclusion, endogenous APC limits cancer cell extravasation because of S(1)P(1)-mediated VE-cadherin-dependent vascular barrier enhancement...
  74. ncbi request reprint Plasma cytokine and P-selectin levels in advanced malignancy: prognostic value and impact of low-molecular weight heparin administration
    Marcello Di Nisio
    Department of Vascular Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
    Cancer 104:2275-81. 2005
    ..The survival benefit described in patients with cancer treated with low molecular weight heparin (LMWH) may result from a LMWH-mediated effect on the immune system or on the cross-talk between platelets and tumor cells...
  75. ncbi request reprint Effects of human cytomegalovirus infection on the coagulation system
    Alessandro Squizzato
    Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands
    Thromb Haemost 93:403-10. 2005
    ..Definitive conclusions, however, cannot be drawn, although the in vitro studies are convincing and offer insight in the pathogenesis...
  76. ncbi request reprint Hypercoagulability in the metabolic syndrome
    Max Nieuwdorp
    Department of Vascular Medicine, AMC, Meibergdreef 9 room F4 159 2, 1100 DD Amsterdam, The Netherlands
    Curr Opin Pharmacol 5:155-9. 2005
    ..In view of the rising incidence of metabolic syndrome even at a young age, both the incidence of venous thromboembolism and the effect of intervention on markers of hypercoagulability in metabolic syndrome call for further studies...